Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.8500 (8.94%) ($5.8500 - $5.8500) on Fri. Jan. 29, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.11% (three month average) | RSI | 75 | Latest Price | $5.8500(8.94%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 4.4% a day on average for past five trading days. | Weekly Trend | ADMS advances 10.7% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XRT(26%) URA(18%) EWY(15%) FIVG(15%) IBUY(14%) | Factors Impacting ADMS price | ADMS will decline at least -2.055% in a week (0% probabilities). XLU(-19%) XLV(-16%) LQD(-9%) IBB(-8%) BND(-8%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.055% (StdDev 4.11%) | Hourly BBV | 1.3 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | 5 Day Moving Average | $5.49(6.56%) | 10 Day Moving Average | $5.06(15.61%) | 20 Day Moving Average | $4.82(21.37%) | To recent high | 0% | To recent low | 17% | Market Cap | $165m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |